Comparative study of levofloxacin and amoxicillin clavulanate potassium in the treatment of community-acquired pneumonia
Objective To compare the clinical effects of levofloxacin and amoxicillin clavulanate potassium in the treatment of communi-ty-acquired pneumonia.Methods A total of 164 hospitalized patients with community-acquired pneumonia from January 2023 to December 2023 were selected for this study.They were divided into group A and group B according to different antimicrobial treatment regiments.Both groups were treated symptomatically with expectorant and cough-relief measures.On this basis,group A was treated with levofloxacin,and group B was treated with amoxicillin and clavulanate potassium.The overall efficacy,the changes of inflammatory indexes before and after treatment,the recovery time of clinical symptoms and the incidence of adverse drug reactions were compared between the two groups.Results The total effective rate of treatment in group A was 97.56%,which was higher than 89.02%in group B(χ2=4.775,P=0.029).The values of CRP,PCT,WBC and NEU%after treatment in the two groups were significantly lower than before treatment,and the inflammatory indexes in group A were significantly lower than those in group B(P＜0.05).The disappearance time of fever,cough and expectoration in group A was shorter than that in group B(P＜0.05).The incidence rate of adverse drug reactions in group A was 2.44%,compared with 3.66%in group B,there was no significant difference(χ2=0.206,P=0.650).Conclusion Compared with amoxicillin clavulanate potassium,levofloxacin has more clinical advantages in the treatment of community-acquired pneumonia,can better control inflammation,shorten the course of disease,and has good safety.
Community acquired pneumoniaLevofloxacinAmoxicillin clavulanate potassium
万方数据
